Ra Phar­ma puts its best foot for­ward with PhII Soliris ri­val, but shares crash af­ter com­par­i­son to Alex­ion’s next-gen drug

Ear­ly this morn­ing, in­ves­ti­ga­tors for Cam­bridge, MA-based Ra Phar­ma­ceu­ti­cals $RARX put their best foot for­ward when they rolled out in­ter­im Phase II da­ta for their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER